Study of Beraprost sodium Tables combination with Aspirin for prevention of type 2 diabetes patients’ atherosclerosis progress

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000919

Enrollment

Unknown

Registered

2010-06-29

Start date

2010-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis

Interventions

A:Beraprost sodium Tables combination with Aspirin

B:Aspirin

Eligibility

Sex/Gender

All

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. T2DM patients between the age of 50 and 75; 2. At least one site IMT>=1.1mm; 3. AST, ALT, SCr<=1.5 times normal value; 4. No ischemic vascular events in 3 months, include myocardial infarction, unstable angina pectoris, stable stenocardia, cerebral arterial thrombosis and hemorrhagic apoplexy; 5. SBP<160 mmHg, DBP<100 mmHg; HbA1c<8.0%; 6. No anti-thrombus drug and antiplatelet drug in last 3 months; 7. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with peptic ulcer or hemorrhage of digestive tract; 2. Drug allergy in PGIS or non-steroidal anti-in-flammatory drugs; 3. Patients who are in suckling period or pregnant and having pregnancy planning; 4. Patients took part in the study in last 3 months or just in the other study now; 5. Patients are not qualified judged by investigator.

Design outcomes

Primary

Measure	Time frame
The change rate of IMT;	—

Secondary

Measure	Time frame
ABI, PWV, SOD, Nitro tyrosine;VCAM-1, TNF-alpha;vascular event;	—

Countries

China

Contacts

Public ContactGuangwei Li

guangwei_li@medmail.com.cn+86 010 84205719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026